German benefit assessment hammers nail in Novartis' aliskiren coffin
This article was originally published in Scrip
Executive Summary
Novartis' antihypertensive Rasilamlo (aliskiren plus amlopidine) offers no proven benefit over comparators, says Germany's Institute for Quality and Eficinecy in Healthcare, IWQiG. The conclusion comes as no surprise. In September the firm stopped marketing the drug in Germany because it did not have the necessary data to make a successful submission under the early benefit assessment.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.